This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
The Event. The Q2 10-Q landed this morning. Cash: $26.7M. Shares outstanding as of today: 43,295,767. Six-month operating cash burn: $13.2M (~$2.2M/month, up from the $1.4M/month I quoted in June). And the line I have been watching since June 3 — whether the ATM stayed quiet after the underwritten raise — is answered: it didn’t. NRx sold $8.4M net via the ATM in Q2 alone, alongside the $20.7M underwritten deal.
The Reaction. $3.58 on August 7 → $3.27 today, -8.7%. That’s the post-Major-Deficiency drawdown continuing to grind, now sitting below the $3.50 June offering print for the first time.
The Reality. The drug thesis on KETAFREE/NRX-100 is unchanged and still tracking. But the “bridged through GDUFA” math I wrote on June 3 was built on a $1.4M/month burn. At $2.2M/month, with the ATM live and management itself saying cash funds drug development only “through at least the first quarter of 2027,” the bridge is shorter than I modeled.
The Receipts
The ATM reactivated — and never really stopped. On June 3 I wrote: “If the ATM reactivates within 60 days, that’s the yellow flag — it would mean management thinks $20M wasn’t enough.” On June 24 I recorded it as “still dormant.” The 10-Q corrects that. Q2 ATM sales were 3,075,990 shares for $8.4M net, on top of 1,736,982 shares for $3.4M net in Q1, on top of the 6,378,942-share underwritten offering at $3.50. Total 2026 issuance: 31,734,333 → 43,295,767 shares, +36.4% in seven and a half months. The implication: the June deal wasn’t a discrete bridge that ended the dilution cycle. It was one large drip inside a continuous one.
The burn rate re-based higher. Cash used in operations for the six months: $13.2M, versus $7.5M in the year-ago period. R&D nearly doubled ($3.4M vs. $1.8M) and SG&A rose to $8.6M from $5.7M, driven by employee, contractor, and marketing costs — i.e., the launch build-out under CCO Glenn Tyson. Why it matters: commercializing costs money before it makes money. My “22–23 months of runway” arithmetic from June 3 assumed $1.4M/month. At the actual $2.2M/month, $26.7M is roughly 12 months — which is precisely why management’s own going-concern language says drug development is funded “through at least the first quarter of 2027,” not through 2028.
Kadima terminated for cause (August 12). The Subsequent Events note discloses that HOPE and HTX delivered a notice of termination to Kadima, declaring the May 2025 purchase agreement terminated for cause and asserting Kadima breached its provisions. Arbitration and litigation both remain pending. The implication: the “quiet drag” I flagged in May and the courtroom I noted on June 24 is now a formal breakup. HOPE’s West Coast leg via Dr. David Feifel is gone for good. The clinic network stands at six Florida locations generating $1.1M of revenue in Q2 against $675K of direct cost — a 39% gross margin on a small base, and a $98K segment operating profit. Real, still small, and no longer growing along the path originally pitched.
The equity grants landed on lock-up expiry (July 28). The Compensation Committee approved 398,353 RSUs to executives — 150,000 to the Executive Chairman, 75,000 to the CEO, 173,353 to the CCO — vesting in three annual tranches. The tea leaf reading: this is the evergreen grab from the March proxy doing exactly what I said it would do. Management’s slice gets topped up as the share count climbs. Note the timing: days before the June-offering insider lock-up rolled off.
Warrant liabilities ballooned to $18.6M. The $9.8M non-cash charge for change in fair value of warrants is why the Q2 net loss reads $16.5M despite a $6.5M operating loss. That’s an accounting artifact of the stock rising into quarter-end, not cash leaving the building — but it’s worth naming because the headline loss looks far worse than the operations. There are still 8,986,823 warrants outstanding at a weighted-average $3.50 strike, with $12.8M of intrinsic value. That’s a real overhang above here.
The Scientific Reality Check
Nothing in this filing touches the science, and that continues to be the point.
The MD&A restates what the August 7 8-K said: FDA completed first-cycle ANDA review with no major deficiencies on drug substance, drug product, CMC, or labeling — only the luer lock vial tip issue, and NRx confirms it “has submitted the documentation requested by FDA from the drug manufacturer.” The manufacturing facility carries VAI status, which is the classification that permits a pre-approval inspection to support an ANDA grant. And here’s the item worth pulling out of the recent-developments table: commercial manufacturing has been initiated at 1-million-dose-per-batch scale, with manufactured drug anticipated by Q3.
That last line matters more than it looks. Committing to a million-dose commercial batch before approval is a cash-consuming vote of confidence — you don’t build inventory at that scale for a product you expect to be rejected. It also explains part of the higher burn. The caveat: pre-approval inventory is a bet, and if the certification review drags, that’s working capital sitting in a warehouse.
On the pipeline sprawl I flagged in May: it got worse, not better. NRXD (military TMS) and GeNeuro (HERV-W antibodies) are now formally incorporated subsidiaries. GeNeuro won two first-round Congressionally Directed Medical Research Program selections totaling $3 million, with final proposals due September 30, 2026 — the first tangible non-dilutive dollars attached to the “funded by sources nondilutive to NRXP” promise. But GeNeuro also discloses that human-grade GNK-301 manufacturing for a first-in-human ALS trial has not been initiated, targeting a July 2027 start. That’s a long, expensive road for a company with twelve months of runway.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.